{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-007678","form_type":"8-K","ticker":"SIGA","cik":"0001010086","company_name":"SIGA TECHNOLOGIES INC","filed_at":"2022-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.036109+00:00","generated_at":"2026-06-27T01:49:24.059014+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SIGA reports 2021 revenue $133.7M, net income $69.5M; EPS $0.91; EMA approves TPOXX","bullets":["FY2021 total revenues $133.7M; net income $69.5M ($0.91 diluted EPS) vs $56.3M ($0.71) in FY2020.","Q4 2021 revenues $115.4M ($73.2M net income, $0.98 EPS) driven by $113M U.S. delivery of oral TPOXX.","International product sales $13M in 2021, up from $2M; EMA approved oral TPOXX in Jan 2022, Health Canada in Dec 2021.","SIGA repurchased ~3.8M shares for $26M in 2021 (~5% of shares outstanding); collaboration with Bioarchitech on immunotherapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-007678","json":"https://secwatch.observer/filing/0001140361-22-007678.json","markdown":"https://secwatch.observer/filing/0001140361-22-007678.md","text":"https://secwatch.observer/filing/0001140361-22-007678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1010086/000114036122007678/0001140361-22-007678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1010086/000114036122007678/brhc10034763_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T01:49:24.059014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}